MedScout has secured US$10m to expand its artificial intelligence tools for medtech commercial teams, more than doubling its valuation from its Series A round.
The company said enterprise revenue has grown threefold since its Series A as medtech companies adopt AI agents to turn commercial strategy into field execution.
Alongside the funding, MedScout is launching Strategies, artificial intelligence agents that analyse market and account-level referral networks, procedure volumes and payer dynamics.
The system produces prioritised territory plans designed for sales representatives.
Co-founder and chief executive officer Skylar Talley said: “MedTech companies spend months developing commercial strategies that don’t make it to the field as intended.
“MedScout bridges that gap by translating commercial priorities into clear, territory-specific actions. Sales reps know which providers to prioritise and how to build and expand those relationships.”
MedScout said commercial teams in the sector often face a disconnect between strategy set at company level and the tools used by representatives in the field.
Sales teams frequently rely on search engines, outdated spreadsheets or data platforms that lack sufficient context.
The funding round was led by Fulcrum Equity Partners, with participation from existing investors Live Oak Venture Partners and Stage 2 Capital.
Philip Lewis, partner at Fulcrum Equity Partners, said: “MedScout is tackling one of the most pressing challenges in MedTech: turning company strategy into revenue performance.
“What they’ve built combines commercial expertise and AI to solve that problem in a highly actionable way that’s unique to each customer.
“This is the future of how companies put AI to work, and it’s why we’re doubling down on our investment in MedScout.”
